Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 44,400 shares, a growth of 114.5% from the June 30th total of 20,700 shares. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is currently 0.0 days.

Scinai Immunotherapeutics Trading Up 15.6 %

NASDAQ SCNI traded up $0.59 during trading hours on Friday, hitting $4.36. 193,624 shares of the company’s stock were exchanged, compared to its average volume of 1,592,664. The firm has a market cap of $2.01 million, a price-to-earnings ratio of -0.02 and a beta of 2.50. The stock has a 50-day simple moving average of $3.70 and a 200 day simple moving average of $4.47. Scinai Immunotherapeutics has a 1-year low of $2.23 and a 1-year high of $14.20.

Scinai Immunotherapeutics (NASDAQ:SCNI) last announced its quarterly earnings data on Tuesday, July 2nd. The company reported ($4.00) earnings per share for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.